Ligand Pharmaceuticals Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Ligand Pharmaceuticals de 23.8% y 16% respectivamente, mientras que el BPA crecerá en un 22.4% al año.

Información clave

23.8%

Tasa de crecimiento de los beneficios

22.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.6%
Tasa de crecimiento de los ingresos	16.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	18 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Oct 31

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 29

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 18

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Jun 29

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

May 23

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27

Ligand Pharmaceuticals: Moving Parts Keep Moving

Mar 29

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Mar 17

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:LGND - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	213	93	92	158	4
12/31/2025	180	66	79	129	6
12/31/2024	156	54	32	88	7
6/30/2024	133	42	-4	48	N/A
3/31/2024	118	96	-17	34	N/A
12/31/2023	131	54	-4	50	N/A
9/30/2023	154	21	90	95	N/A
6/30/2023	180	41	99	108	N/A
3/31/2023	204	51	104	120	N/A
12/31/2022	196	-5	120	138	N/A
9/30/2022	183	23	95	112	N/A
6/30/2022	188	27	97	112	N/A
3/31/2022	223	45	110	120	N/A
12/31/2021	242	76	71	79	N/A
9/30/2021	275	68	45	52	N/A
6/30/2021	252	48	37	44	N/A
3/31/2021	208	39	42	48	N/A
12/31/2020	164	7	51	55	N/A
9/30/2020	143	-16	41	47	N/A
6/30/2020	126	-25	24	28	N/A
3/31/2020	110	-61	-60	-58	N/A
12/31/2019	120	629	781	-29	N/A
9/30/2019	153	594	812	11	N/A
6/30/2019	174	677	846	44	N/A
3/31/2019	239	764	980	179	N/A
12/31/2018	251	143	183	194	N/A
9/30/2018	242	179	198	193	N/A
6/30/2018	230	120	196	193	N/A
3/31/2018	168	53	N/A	130	N/A
12/31/2017	141	13	N/A	89	N/A
9/30/2017	129	16	N/A	78	N/A
6/30/2017	117	9	N/A	69	N/A
3/31/2017	109	-3	N/A	69	N/A
12/31/2016	109	-2	N/A	61	N/A
9/30/2016	92	7	N/A	56	N/A
6/30/2016	88	205	N/A	48	N/A
3/31/2016	87	235	N/A	47	N/A
12/31/2015	72	230	N/A	42	N/A
9/30/2015	74	231	N/A	38	N/A
6/30/2015	71	33	N/A	32	N/A
3/31/2015	63	11	N/A	26	N/A
12/31/2014	65	12	N/A	21	N/A
9/30/2014	56	7	N/A	22	N/A
6/30/2014	54	8	N/A	18	N/A
3/31/2014	53	10	N/A	21	N/A
12/31/2013	49	9	N/A	21	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (23.8% al año) de LGND es superior a la tasa de ahorro (2.5%).

Beneficios vs. Mercado: Se prevé que los beneficios (23.8% al año) de LGND crezcan más rápidamente que el mercado US (15.2% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de LGND crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (16% al año) de LGND crezcan más rápidamente que los del mercado US (8.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 16% al año) de LGND crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de LGND se prevé que sea elevada dentro de 3 años.

Ligand Pharmaceuticals Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Ligand Pharmaceuticals Incorporated Reaffirms Financial Guidance for the Full Year of 2024

Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024

Consensus EPS estimates increase by 199%

Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024

Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024

Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2024

Recent updates

Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Ligand Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 07, 2024

Ligand Pharmaceuticals Incorporated Reaffirms Financial Guidance for the Full Year of 2024

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Ligand Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 06, 2024

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into an agreement to acquire APEIRON Biologics AG for $128 million.

Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

Chief Financial Officer notifies of intention to sell stock

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

President & COO recently sold US$1.5m worth of stock

Consensus EPS estimates increase by 199%

Chief Legal Officer & Secretary notifies of intention to sell stock

First quarter 2024 earnings released: EPS: US$4.86 (vs US$2.56 in 1Q 2023)

Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Jun 14, 2024

Ligand Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 07, 2024

Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

CEO & Director exercised options to buy US$1.2m worth of stock.

Chief Financial Officer notifies of intention to sell stock

Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Announces Management Appointments

Ligand Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 27, 2024

U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 28%, revenue upgraded

Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ligand Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 08, 2023

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

CEO & Director recently bought US$238k worth of stock

Ligand Pharmaceuticals Incorporated Appoints Martine Zimmermann to its Board of Directors

Ligand Pharmaceuticals Incorporated Reaffirms Revenue Guidance for 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) announces an Equity Buyback for $50 million worth of its shares.

Ligand's Collaborator Merck Announces V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

Ligand Pharmaceuticals Incorporated to Report Q2, 2023 Results on Aug 08, 2023

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into a stalking horse asset purchase agreement to acquire Substantially All of the Assets of Novan, Inc. for $15 million.

Consensus EPS estimates increase by 73%

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Independent Chairman recently sold US$343k worth of stock

Independent Chairman notifies of intention to sell stock

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

Ligand Pharmaceuticals Incorporated Raises Earnings Guidance for 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 41%

Full year 2022 earnings released: US$0.31 loss per share (vs US$3.44 profit in FY 2021)

Ligand Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 22, 2023

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Executive Director notifies of intention to sell stock

Executive Director exercised options to buy US$998k worth of stock.

Ligand Pharmaceuticals Incorporated Announces CEO Changes

Price target decreased to US$111

CEO & Executive Director notifies of intention to sell stock

Consensus revenue estimates increase by 18%

Insufficient new directors

Chief Financial Officer recently sold US$128k worth of stock

Price target decreased to US$131

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Provides Revenue Guidance for the Year 2022

Insufficient new directors

Ligand Pharmaceuticals Incorporated Appoints Octavio (Tavo) Espinoza as Chief Financial Officer

Ligand Pharmaceuticals Incorporated to Report Q3, 2022 Results on Nov 07, 2022